SOPHiA GENETICS Reports Second Quarter 2025 Results

, /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-year Gross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported and 73.2% adjusted in the prior year period IFRS net loss increased 48% year-over-year to $22.4 million (or 23% excluding foreign exchange impact); Adjusted EBITDA loss increased 33% to $11.7 million; Cash burn improved 35% to $8.7 million (or 10% excluding foreign exchange impact) The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We delivered another strong quarter of revenue growth in Q2 with 16% year-over-year growth, as new business continues to ramp and transformative applications like MSK-ACCESS® powered with SOPHiA DDMTM gain adoption," said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder. "The scalable, hyper-efficient data processing capabilities of SOPHiA DDMTM enabled us to expand adjusted gross margins by 120bps year-over-year to 74.4%, despite the increase in volume and data computed. This, in combination with prudent cost management, brought cash burn to $8.7 million in the quarter, a 35% improvement year-over-year." Camblong added, "In addition to the strong performance, we also secured impressive new business wins in Q2 to fuel future growth. We signed 35 new core genomics customers in Q2 by capitalizing on robust Clinical demand across geographies and innovative new applications. We also announced the largest contract in company history with the signing of a multi-year AI breast cancer partnership with AstraZeneca, which demonstrates the significant value of the SOPHiA GENETICS's network and AI capabilities to BioPharma." Second Quarter 2025 Business Highlights Expanding usage of SOPHiA DDMTM worldwide Performed 95,000 analyses on SOPHiA DDMTM, representing 9% year-over-year volume growth Reached 490 core genomics customers as of June 30, 2025, up from 457 customers at the end of Q2 2024 Recorded the first wave of material volume from MSK-ACCESS® powered with SOPHiA DDMTM , the new, sophisticated Liquid Biopsy application carrying higher-than-average selling prices Significantly expanded our long-standing partnership with Dasa, the largest medical diagnostics company in Latin America; Dasa is adopting HemOnc and Rare Disease applications in addition to the Hereditary Cancer, Solid Tumor, and Liquid Biopsy applications they run today Landing new Clinical customers to fuel future Platform growth Continued delivering robust new business momentum by landing an all-time high of 35 new customers in Q2 2025 who will implement SOPHiA DDMTM and begin generating revenue over the next twelve months, up from 19 new customers signed in Q2 2024 Signed major new customers in the central lab category, including Igenomix, a global reproductive health and fertility reference lab, who is adopting SOPHiA DDMTM for Rare and Inherited Disorder applications, and Simply PCR in Toronto, Canada, who is adopting MSK-ACCESS® powered with SOPHiA DDMTM Accelerating growth with new applications Signed 11 new customers to MSK-ACCESS® powered with SOPHiA DDMTM in Q2, including King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia; Hospital del Mar Research Institute in Barcelona, Spain; Instituto Oncologico Veneto in Padua, Italy; Tata Memorial Hospital in Mumbai, India; and Royal North Shore Hospital in Sydney, Australia Reached a total of 50 customers signed-to-adopt the Liquid Biopsy application MSK-ACCESS® powered with SOPHiA DDMTM, with the majority expected to complete implementation and begin generating revenue over the next 6 months Driving strong business growth in the U.S. market Delivered over 19% year-over-year U.S. revenue growth excluding BioPharma in Q2 2025 Signed major new customers including The University of California (UC), Irvine Pathology Lab who is adopting Solid Tumor and HemOnc applications and The University of Alabama Birmingham (UAB) Hospital who is adopting SOPHiA DDMTM for HemOnc Leveraging SOPHiA DDMTM to deliver value to BioPharma partners Signed a major, multi-year expansion of the partnership with AstraZeneca to leverage SOPHiA GENETICS's multimodal AI factories to optimize outcomes for individuals undergoing treatment for breast cancer Engaged to (1) develop a bespoke AI-powered predictive model aimed at optimizing breast cancer patient outcomes and (2) generate real-world evidence in Europe and North America to uncover key drivers of treatment efficacy, address critical knowledge gaps, and enhance clinical decision-making through deeper insights Growing sustainably by maintaining an obsession with operational excellence Achieved a 74.4% adjusted gross margin, up 120bps year-over-year, by continuing to optimize compute costs and leverage the scale of the cloud-native SOPHiA DDMTM platform Ended Q2 2025 with $94.8 million in cash and cash equivalents after drawing $35 million as part of the second tranche of the credit facility available with Perceptive Advisors, strengthening our capital position to support future growth initiatives The Company reaffirms commitment to profitable growth and expects to be approaching adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027 2025 Financial Outlook Based on information as of today, SOPHiA GENETICS is reaffirming the previously provided guidance of: Full-year revenue between $72 million and $76 million, representing growth of approximately 10% to 17% compared to FY 2024 Adjusted EBITDA loss between $35 million and $39 million, compared to $40.2 million in FY 2024 Non-IFRS Financial Measures Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted operating loss (non-IFRS measure) to operating loss (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses and intangible assets, share-based compensation expenses, and non-cash portion of pensions paid in excess of actual contributions, that are necessary for such reconciliation. To provide investors with additional information regarding the company's financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures: Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses; Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue; Adjusted operating loss, which the company calculates as operating loss adjusted to exclude amortization of capitalized research and development expenses, amortization of intangible assets, share-based compensation expense, and non-cash portion of pensions expense paid in excess of actual contributions to match the actuarial expense. EBITDA, which the company calculates as loss for the year before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, and income tax (expense) benefit; and Adjusted EBITDA, which the company calculates as EBITDA adjusted to exclude share-based compensation expense, non-cash pension expenses, and costs associated with restructuring. These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors. These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS' results as reported under IFRS. Some of these limitations are: These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures; These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company's financial liabilities; These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company's financial assets; These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates; These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company's functional currency; These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations; These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures; These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company's business and an important part of its compensation strategy; These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business; and Other companies, including companies in the company's industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures. Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results. The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented. Presentation of Constant Currency Revenue SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company's customers' geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure "constant currency revenue" (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term "constant currency", it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the "constant currency impact" for the current period. The company's management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results. The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period. Earnings Call and Webcast Information SOPHiA GENETICS will host a conference call and live webcast to discuss the second quarter 2025 results on Tuesday, August 5, 2025, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. Forward-Looking Statements This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. SOPHiA GENETICS SAInterim Condensed Consolidated Statements of Loss(Amounts in USD thousands, except per share data)(Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue $ 18,323 $ 15,808 $ 36,102 $ 31,587 Cost of revenue (6,053) (5,032) (11,624) (10,406) Gross profit 12,270 10,776 24,478 21,181 Research and development costs (8,493) (7,958) (17,611) (17,349) Selling and marketing costs (10,034) (7,258) (17,568) (14,209) General and administrative costs (12,301) (10,583) (23,901) (23,408) Other operating income, net 66 18 74 24 Operating loss (18,492) (15,005) (34,528) (33,761) Interest income 419 951 869 1,852 Interest expense (559) (501) (1,218) (644) Fair value adjustments on warrant obligations 58 84 20 84 Foreign exchange (losses) gains, net (3,078) (561) (3,677) 4,049 Loss before income taxes (21,652) (15,032) (38,534) (28,420) Income tax expense (762) (161) (1,265) (477) Loss for the period (22,414) (15,193) (39,799) (28,897) Attributable to the owners of the parent (22,414) (15,193) (39,799) (28,897) Basic and diluted loss per share $ (0.33) $ (0.23) $ (0.59) $ (0.44) SOPHiA GENETICS SAInterim Condensed Consolidated Statements of Comprehensive Loss(Amounts in USD thousands)(Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Loss for the period $ (22,414) $ (15,193) $ (39,799) $ (28,897) Other comprehensive (loss) income: Items that may be reclassified to statement of loss Currency translation adjustments 9,016 252 11,602 (9,139) Total items that may be reclassified to statement ofloss 9,016 252 11,602 (9,139) Items that will not be reclassified to statement of loss(net of tax) Remeasurement of defined benefit plans 46 (41) 93 (58) Total items that will not be reclassified to statementof loss 46 (41) 93 (58) Other comprehensive (loss) income for the period $ 9,062 $ 211 $ 11,695 $ (9,197) Total comprehensive loss for the period $ (13,352) $ (14,982) $ (28,104) $ (38,094) Attributable to owners of the parent $ (13,352) $ (14,982) $ (28,104) $ (38,094) SOPHiA GENETICS SAInterim Condensed Consolidated Balance Sheets(Amounts in USD thousands)(Unaudited) June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 94,822 $ 80,226 Accounts receivable 9,505 7,436 Inventory 6,217 5,868 Prepaids and other current assets 6,490 5,875 Total current assets 117,034 99,405 Non-current assets Property and equipment 5,139 5,209 Intangible assets 33,730 28,998 Right-of-use assets 13,331 14,168 Deferred tax assets 1,753 1,767 Other non-current assets 6,633 5,762 Total non-current assets 60,586 55,904 Total assets $ 177,620 $ 155,309 Liabilities and equity Current liabilities Accounts payable $ 7,733 $ 5,220 Accrued expenses 13,722 13,217 Deferred contract revenue 9,649 5,732 Lease liabilities, current portion 2,485 2,190 Warrant obligations 896 444 Total current liabilities 34,485 26,803 Non-current liabilities Borrowings 47,466 13,237 Lease liabilities, net of current portion 13,862 14,603 Defined benefit pension liabilities 4,489 3,839 Other non-current liabilities 626 337 Total non-current liabilities 66,443 32,016 Total liabilities 100,928 58,819 Equity Share capital 4,188 4,188 Share premium 472,355 472,244 Treasury shares (648) (702) Other reserves 80,873 61,037 Accumulated deficit (480,076) (440,277) Total equity 76,692 96,490 Total liabilities and equity $ 177,620 $ 155,309 SOPHiA GENETICS SAInterim Condensed Consolidated Statements of Cash Flows(Amounts in USD thousands)(Unaudited) Six months ended June 30, 2025 2024 (As Recast)1 Operating activities Loss before tax $ (38,534) $ (28,420) Adjustments for non-monetary items Depreciation 1,927 2,287 Amortization 2,740 1,809 Finance expense (income), net 4,037 (5,747) Fair value adjustments on warrant obligations (20) (84) Expected credit loss allowance increase (reversal) 252 (34) Share-based compensation 8,191 7,797 Movements in provisions and pensions 304 410 Research tax credit (528) (283) Working capital changes (Increase) decrease in accounts receivable (1,298) 3,042 Decrease in prepaids and other assets 934 934 Decrease (increase) in inventory 362 (655) Increase (decrease) in accounts payables, accrued expenses, deferred contract revenue, and other liabilities 2,815 (6,100) Cash used in operating activities (18,818) (25,044) Income tax paid (146) (18) Net cash flows used in operating activities (18,964) (25,062) Investing activities Purchase of property and equipment (130) (111) Acquisition of intangible assets (87) (167) Capitalized development costs (3,250) (3,637) Interest received 876 1,795 Net cash flow used in investing activities (2,591) (2,120) Financing activities Proceeds from exercise of share options 115 298 Interest paid (1,240) (572) Proceeds from borrowings, net of transaction costs 34,563 13,930 Payments of principal portion of lease liabilities (889) (1,477) Net cash flow provided by financing activities 32,549 12,179 Increase (decrease) in cash and cash equivalents 10,994 (15,003) Effect of exchange differences on cash balances 3,602 (2,852) Cash and cash equivalents at beginning of the year 80,226 123,251 Cash and cash equivalents at end of the period $ 94,822 $ 105,396 1 Refer to "Note 1—Change in accounting policies—Statement of Cash Flows - Interest Classification", included as Exhibit 99.1 to the Report on Form 6-K to which this report is included as Exhibit 99.3, for details on change in accounting policy. SOPHiA GENETICS SA Reconciliation of IFRS Net Loss to Adjusted EBITDA (Amounts in USD thousands) (Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Loss for the period $ (22,414) $ (15,193) $ (39,799) $ (28,897) Exclude the impact of: Depreciation $ 942 $ 1,129 $ 1,927 $ 2,287 Amortization 1,428 909 2,740 1,809 Interest income (419) (951) (869) (1,852) Interest expense 559 501 1,218 644 Fair value adjustments on warrant obligations (58) (84) (20) (84) Foreign exchange losses (gains), net 3,078 561 3,677 (4,049) Income tax expense 762 161 1,265 477 Share-based compensation expense(1) 4,356 4,083 8,191 7,797 Non-cash pension expense(2) 89 96 175 173 Adjusted EBITDA $ (11,677) $ (8,788) $ (21,495) $ (21,695) SOPHiA GENETICS SAReconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth(Amounts in USD thousands, except for %)(Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 Growth 2025 2024 Growth IFRS revenue $ 18,323 $ 15,808 16 % $ 36,102 $ 31,587 14 % Current period constant currency impact (583) — — (165) — Constant currency revenue $ 17,740 $ 15,808 12 % $ 35,937 $ 31,587 14 % SOPHiA GENETICS SAReconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin(Amounts in USD thousands, except percentages)(Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue $ 18,323 $ 15,808 $ 36,102 $ 31,587 Cost of revenue (6,053) (5,032) (11,624) (10,406) Gross profit $ 12,270 $ 10,776 $ 24,478 $ 21,181 Amortization of capitalized research and development expenses(3) 1,357 794 2,598 1,521 Adjusted gross profit $ 13,627 $ 11,570 $ 27,076 $ 22,702 Gross profit margin 67.0 % 68.2 % 67.8 % 67.1 % Amortization of capitalized research and development expenses(3) 7.4 % 5.0 % 7.2 % 4.8 % Adjusted gross profit margin 74.4 % 73.2 % 75.0 % 71.9 % SOPHiA GENETICS SAReconciliation of IFRS to Adjusted Operating Loss for the Period(Amounts in USD thousands)(Unaudited) Three months endedJune 30, Six months ended June 30, 2025 2024 2025 2024 Operating loss $ (18,492) $ (15,005) $ (34,528) $ (33,761) Amortization of capitalized research & development expenses(3) 1,357 794 2,598 1,521 Amortization of intangible assets(4) 71 114 142 288 Share-based compensation expense(1) 4,356 4,084 8,191 7,797 Non-cash pension expense(2) 89 96 175 173 Adjusted operating loss $ (12,619) $ (9,917) $ (23,422) $ (23,982) Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables (1) Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy. (2) Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense but remains a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future. (3) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives. (4) Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments. SOURCE SOPHiA GENETICS WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

SOPHiA GENETICS Reports Second Quarter 2025 Results

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News